$RENE
Cartesian Growth Corp II

2024 Q3 Form 10-Q Financial Statement

#000141057824001897 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $217.0K
YoY Change -1.35%
Operating Profit -$217.0K
YoY Change -0.58%
Interest Expense $2.340M
YoY Change -26.87%
% of Operating Profit
Other Income/Expense, Net $3.126M
YoY Change 49.95%
Pretax Income $2.909M
YoY Change 55.58%
Income Tax
% Of Pretax Income
Net Earnings $2.909M
YoY Change 55.86%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.13
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $199.8K
YoY Change
Cash & Equivalents $199.8K
Short-Term Investments
Other Short-Term Assets $51.56K
YoY Change -48.44%
Inventory
Prepaid Expenses $51.56K
Receivables
Other Receivables
Total Short-Term Assets $251.3K
YoY Change 211.89%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $182.5M
YoY Change -26.61%
Other Assets
YoY Change
Total Long-Term Assets $182.5M
YoY Change -26.6%
TOTAL ASSETS
Total Short-Term Assets $251.3K
Total Long-Term Assets $182.5M
Total Assets $182.8M
YoY Change -26.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $1.291M
YoY Change 491.7%
Deferred Revenue
YoY Change
Short-Term Debt $1.650M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.941M
YoY Change 1248.07%
LONG-TERM LIABILITIES
Long-Term Debt $4.079M
YoY Change 19.98%
Other Long-Term Liabilities $12.49M
YoY Change 362.74%
Total Long-Term Liabilities $16.57M
YoY Change 171.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.941M
Total Long-Term Liabilities $16.57M
Total Liabilities $19.51M
YoY Change 9.95%
SHAREHOLDERS EQUITY
Retained Earnings -$19.26M
YoY Change 9.03%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$19.26M
YoY Change
Total Liabilities & Shareholders Equity $182.8M
YoY Change -26.52%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income $2.909M
YoY Change 55.86%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$88.30K
YoY Change -53.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$450.0K
YoY Change
Cash From Investing Activities -$450.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 700.0K
YoY Change
NET CHANGE
Cash From Operating Activities -88.30K
Cash From Investing Activities -450.0K
Cash From Financing Activities 700.0K
Net Change In Cash 161.7K
YoY Change -185.11%
FREE CASH FLOW
Cash From Operating Activities -$88.30K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Notes Payable Noncurrent Related Party Type Extensible Enumeration
NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001889112
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q3 us-gaap Notes Payable Noncurrent Related Party Type Extensible Enumeration
NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 rene Business Combination Term By Which Period To Consummate Initial Business Combination Is Extended
BusinessCombinationTermByWhichPeriodToConsummateInitialBusinessCombinationIsExtended
P1M
CY2023Q4 rene Business Combination Term By Which Period To Consummate Initial Business Combination Is Extended
BusinessCombinationTermByWhichPeriodToConsummateInitialBusinessCombinationIsExtended
P1M
rene Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences
ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
P150D
rene Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences
ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
P150D
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2023Q1 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2023Q2 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2023Q3 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2024Q1 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2024Q2 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2024Q3 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2023 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2024Q1 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2024Q2 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2024Q3 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41378
dei Entity Registrant Name
EntityRegistrantName
CARTESIAN GROWTH CORPORATION II
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Address Address Line1
EntityAddressAddressLine1
505 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
15th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
461-6363
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2024Q3 us-gaap Cash
Cash
199764
CY2023Q4 us-gaap Cash
Cash
50932
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51560
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
279102
CY2024Q3 us-gaap Assets Current
AssetsCurrent
251324
CY2023Q4 us-gaap Assets Current
AssetsCurrent
330034
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
182526592
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
174252198
CY2024Q3 us-gaap Assets
Assets
182777916
CY2023Q4 us-gaap Assets
Assets
174582232
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1290771
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1230978
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1650000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
300000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2940771
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1530978
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
994000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
2162323
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
4079206
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3676685
CY2024Q3 rene Deferred Underwriting Fee Non Current
DeferredUnderwritingFeeNonCurrent
11500000
CY2023Q4 rene Deferred Underwriting Fee Non Current
DeferredUnderwritingFeeNonCurrent
11500000
CY2024Q3 us-gaap Liabilities
Liabilities
19513977
CY2023Q4 us-gaap Liabilities
Liabilities
18869986
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19263228
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18540527
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-19262653
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-18539952
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182777916
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
174582232
CY2024Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
217022
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
218279
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
638503
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
769055
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-217022
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-218279
us-gaap Operating Income Loss
OperatingIncomeLoss
-638503
us-gaap Operating Income Loss
OperatingIncomeLoss
-769055
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-679233
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10309
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1168323
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1155723
CY2024Q3 rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
-106975
CY2023Q3 rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
1102459
rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
-97479
rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
15494
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2340228
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3197705
us-gaap Investment Income Interest
InvestmentIncomeInterest
6924394
us-gaap Investment Income Interest
InvestmentIncomeInterest
8925457
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3126436
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2084937
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8190196
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10065686
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
2909414
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
1866658
us-gaap Net Income Loss
NetIncomeLoss
7551693
us-gaap Net Income Loss
NetIncomeLoss
9296631
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-18539952
CY2024Q1 rene Adjustments To Additional Paid In Capital Remeasurement For Ordinary Shares To Redemption Amount
AdjustmentsToAdditionalPaidInCapitalRemeasurementForOrdinarySharesToRedemptionAmount
2726486
CY2024Q1 us-gaap Profit Loss
ProfitLoss
2534872
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-18731566
CY2024Q2 rene Adjustments To Additional Paid In Capital Remeasurement For Ordinary Shares To Redemption Amount
AdjustmentsToAdditionalPaidInCapitalRemeasurementForOrdinarySharesToRedemptionAmount
2757680
CY2024Q2 us-gaap Profit Loss
ProfitLoss
2107407
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-19381839
CY2024Q3 rene Adjustments To Additional Paid In Capital Remeasurement For Ordinary Shares To Redemption Amount
AdjustmentsToAdditionalPaidInCapitalRemeasurementForOrdinarySharesToRedemptionAmount
2790228
CY2024Q3 us-gaap Profit Loss
ProfitLoss
2909414
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-19262653
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-18038139
CY2023Q1 rene Adjustments To Additional Paid In Capital Remeasurement For Ordinary Shares To Redemption Amount
AdjustmentsToAdditionalPaidInCapitalRemeasurementForOrdinarySharesToRedemptionAmount
2902118
CY2023Q1 us-gaap Profit Loss
ProfitLoss
3710757
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-17229500
CY2023Q2 rene Adjustments To Additional Paid In Capital Remeasurement For Ordinary Shares To Redemption Amount
AdjustmentsToAdditionalPaidInCapitalRemeasurementForOrdinarySharesToRedemptionAmount
2825634
CY2023Q2 us-gaap Profit Loss
ProfitLoss
3719216
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-16335918
CY2023Q3 rene Adjustments To Additional Paid In Capital Remeasurement For Ordinary Shares To Redemption Amount
AdjustmentsToAdditionalPaidInCapitalRemeasurementForOrdinarySharesToRedemptionAmount
3197705
CY2023Q3 us-gaap Profit Loss
ProfitLoss
1866658
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-17666965
us-gaap Profit Loss
ProfitLoss
7551693
us-gaap Profit Loss
ProfitLoss
9296631
us-gaap Investment Income Interest
InvestmentIncomeInterest
6924394
us-gaap Investment Income Interest
InvestmentIncomeInterest
8925457
rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
-97479
rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
15494
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1168323
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1155723
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-227542
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-253134
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
59793
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
69235
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-351168
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-446686
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
1350000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1350000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1350000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
500000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
70000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1850000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-70000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
148832
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-516686
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50932
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
543667
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199764
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26981
rene Remeasurement Of Ordinary Shares Subject To Possible Redemption
RemeasurementOfOrdinarySharesSubjectToPossibleRedemption
8274394
rene Remeasurement Of Ordinary Shares Subject To Possible Redemption
RemeasurementOfOrdinarySharesSubjectToPossibleRedemption
8925457
CY2022Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
23000000
CY2023Q4 rene Business Combination Maximum Number Of Extensions Authorized To Consummate Initial Business Combination
BusinessCombinationMaximumNumberOfExtensionsAuthorizedToConsummateInitialBusinessCombination
12
CY2023Q4 rene Business Combination Term By Which Period To Consummate Initial Business Combination Is Extended
BusinessCombinationTermByWhichPeriodToConsummateInitialBusinessCombinationIsExtended
P1M
CY2023Q4 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
150000
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.02
CY2023Q4 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
7129439
CY2023Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.86
CY2023Q4 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
77400000
CY2023Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
172400000
CY2023Q4 rene Extension Payment Deposited In Trust Account
ExtensionPaymentDepositedInTrustAccount
150000
CY2023Q4 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
150000
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.02
CY2023Q4 rene Business Combination Maximum Number Of Extensions Authorized To Consummate Initial Business Combination
BusinessCombinationMaximumNumberOfExtensionsAuthorizedToConsummateInitialBusinessCombination
12
CY2023Q4 rene Public Share Price Per Share
PublicSharePricePerShare
10.30
CY2023Q4 us-gaap Interest Expense Other
InterestExpenseOther
100000
CY2023Q4 rene Public Share Price Per Share
PublicSharePricePerShare
10.30
CY2023Q4 rene Public Share Price Per Share
PublicSharePricePerShare
10.30
CY2024Q3 us-gaap Cash
Cash
199764
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
182526592
CY2024Q3 rene Working Capital
WorkingCapital
2689447
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2024Q3 us-gaap Cash
Cash
199764
CY2023Q4 us-gaap Cash
Cash
50932
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
rene Offering Costs
OfferingCosts
16804728
rene Offering Costs Charged To Shareholders Deficit
OfferingCostsChargedToShareholdersDeficit
16608744
rene Offering Costs Charged To Operations
OfferingCostsChargedToOperations
195984
rene Dissolution Expenses
DissolutionExpenses
100000
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging – Contracts in Entity’s Own Equity” (“ASC 815-40”). The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</p>
rene Percentage Of Proceeds From Share Issuances
PercentageOfProceedsFromShareIssuances
0.60
rene Period After Completion Of Initial Business Combination
PeriodAfterCompletionOfInitialBusinessCombination
P30D
CY2021Q4 us-gaap Sponsor Fees
SponsorFees
25000
CY2021Q4 rene Price Per Share Unit
PricePerShareUnit
0.004
CY2021Q4 rene Assets Tangible And Intangible
AssetsTangibleAndIntangible
0
CY2021Q4 rene Percentage Of Founder Shares
PercentageOfFounderShares
0.20
rene Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Trading Days
TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays
20
rene Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Consecutive Trading Days
TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
30
CY2022Q2 rene Office Space Monthly Rent
OfficeSpaceMonthlyRent
10000
CY2022Q3 rene Office Space Monthly Rent
OfficeSpaceMonthlyRent
10000
CY2023Q4 rene Extension Payment Deposited In Trust Account
ExtensionPaymentDepositedInTrustAccount
150000
CY2023Q4 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
150000
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.02
CY2023Q4 rene Business Combination Term By Which Period To Consummate Initial Business Combination Is Extended
BusinessCombinationTermByWhichPeriodToConsummateInitialBusinessCombinationIsExtended
P1M
CY2024Q3 rene Working Capital Loan
WorkingCapitalLoan
1500000
rene Price Per Warrant
PricePerWarrant
1.00
rene Number Of Demands Eligible Security Holder Can Make
NumberOfDemandsEligibleSecurityHolderCanMake
3
rene Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Stock Price Trigger
TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger
12.00
rene Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Trading Days
TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays
20
rene Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Consecutive Trading Days
TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
30
rene Period After Completion Of Initial Business Combination
PeriodAfterCompletionOfInitialBusinessCombination
P30D
us-gaap Legal Fees
LegalFees
1200000
us-gaap Legal Fees
LegalFees
900000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Sale Of Stock Percentage Of Ownership Before Transaction
SaleOfStockPercentageOfOwnershipBeforeTransaction
0.20
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16566666
rene Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Initial Measurement
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialMeasurement
5533268
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-680330
rene Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 To Level1
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3ToLevel1
-2750475
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2102463
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-567883
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1534580
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-76816
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1457764
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-13458
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1444306
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1165656
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-245396
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
920260
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-21360
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
898900
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-364900
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
534000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001897-index-headers.html Edgar Link pending
0001410578-24-001897-index.html Edgar Link pending
0001410578-24-001897.txt Edgar Link pending
0001410578-24-001897-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240930.xsd Edgar Link pending
tmb-20240930x10q.htm Edgar Link pending
tmb-20240930xex31d1.htm Edgar Link pending
tmb-20240930xex31d2.htm Edgar Link pending
tmb-20240930xex32d1.htm Edgar Link pending
tmb-20240930xex32d2.htm Edgar Link pending
tmb-20240930_def.xml Edgar Link unprocessable
tmb-20240930_pre.xml Edgar Link unprocessable
tmb-20240930x10q_htm.xml Edgar Link completed
tmb-20240930_cal.xml Edgar Link unprocessable
tmb-20240930_lab.xml Edgar Link unprocessable